<span style="font-size: 110%; font-family: arial,sans,sans-serif;" data-sheets-value="[null,2,"Current clinical trials are examining the possibility of giving kidney cancer (also called renal cell carcinoma, or RCC) patients immunotherapy as their first option of care upon diagnosis."]" data-sheets-userformat="[null,null,8833,[null,1],null,null,null,null,null,null,0,null,0,null,null,null,11]">Current clinical trials are examining the possibility of giving kidney cancer (also called renal cell carcinoma, or RCC) patients immunotherapy as their first option of care upon diagnosis.

Current clinical trials are examining the possibility of giving kidney cancer (also called renal cell carcinoma, or RCC) patients immunotherapy as their first option of care upon diagnosis.

Current clinical trials are examining the possibility of giving kidney cancer (also called renal cell carcinoma, or RCC) patients immunotherapy as their first option of care upon diagnosis.

Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers.  The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Science

Medicine

Health & Fitness

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Share Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?

Sign up to save your podcasts

Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?

Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?